A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

Rafael Amado Biography and Net Worth

President, Head of Global Research and Development of Zai Lab

Rafael G. Amado, M.D., joined Zai Lab in December 2022 and currently serves as President, Head of Global Research and Development.

Prior to joining Zai Lab, Dr. Amado was the Executive Vice President, Head of Research and Development and Chief Medical Officer for Allogene Therapeutics, Inc. Before joining Allogene, Dr. Amado served as President of Research and Development and Chief Medical Officer of Adaptimmune, LLC from August 2018 to July 2019 and as Chief Medical Officer from March 2015 to July 2018. In these roles, he was responsible for directing discovery and clinical development strategy as well as execution activities for several gene-engineered cell therapies, chairing the R&D leadership team and providing medical guidance for pipeline prioritization. Prior to Adaptimmune, Dr. Amado held various roles of increasing responsibility at GlaxoSmithKline from 2008 to 2015, most recently as Senior Vice President and Global Head of Oncology Research and Development, and at Amgen Inc. from 2003 to 2008, where he was last Executive Director of Clinical Research and Global Development in Therapeutic Oncology.

Dr. Amado received an M.D. from the University of Seville School of Medicine in Seville, Spain and completed his internship and residency in Internal Medicine at the Michael Reese Hospital and Medical Center and a fellowship in Hematology / Oncology at UCLA.

What is Rafael Amado's net worth?: The estimated net worth of Rafael Amado is at least $611,429.99 as of March 15th, 2024. Dr. Amado owns 20,093 shares of Zai Lab stock worth more than $611,430 as of October 31st. This net worth evaluation does not reflect any other investments that Dr. Amado may own. Additionally, Dr. Amado receives a salary of $1,600,000.00 as President, Head of Global Research and Development at Zai Lab. Learn More about Rafael Amado's net worth.
How old is Rafael Amado?: Dr. Amado is currently 60 years old. There are 6 older executives and no younger executives at Zai Lab. Learn More on Rafael Amado's age.
What is Rafael Amado's salary?: As the President, Head of Global Research and Development of Zai Lab Limited, Dr. Amado earns $1,600,000.00 per year. The highest earning executive at Zai Lab is Dr. Ying Du Ph.D., Founder, Chairperson & CEO, who commands a salary of $1,700,000.00 per year. Learn More on Rafael Amado's salary.
How do I contact Rafael Amado?: The corporate mailing address for Dr. Amado and other Zai Lab executives is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. Zai Lab can also be reached via phone at 862161632588 and via email at [email protected]. Learn More on Rafael Amado's contact information.
Has Rafael Amado been buying or selling shares of Zai Lab?: Rafael Amado has not been actively trading shares of Zai Lab during the last quarter. Most recently, Rafael Amado sold 2,544 shares of the business's stock in a transaction on Friday, March 15th. The shares were sold at an average price of $18.86, for a transaction totalling $47,979.84. Following the completion of the sale, the insider now directly owns 20,093 shares of the company's stock, valued at $378,953.98. Learn More on Rafael Amado's trading history.
Who are Zai Lab's active insiders?: Zai Lab's insider roster includes Rafael Amado (President, Head of Global Research and Development), Kai-Xian Chen (Director), Yajing Chen (CFO), William Cho (CFO), John Diekman (Director), Ying Du (CEO), Frazor Edmondson, III (Insider), Tao Fu (COO), William Lis (Director), Harald Reinhart (Insider), Joshua Smiley (Insider), and Peter Wirth (Director). Learn More on Zai Lab's active insiders.
Are insiders buying or selling shares of Zai Lab?: During the last twelve months, Zai Lab insiders bought shares 2 times. They purchased a total of 9,000 shares worth more than $254,250.00. During the last twelve months, insiders at the sold shares 16 times. They sold a total of 105,762 shares worth more than $2,129,393.77. The most recent insider tranaction occured on August, 16th when insider Joshua L Smiley sold 4,352 shares worth more than $72,547.84. Insiders at Zai Lab own 5.2% of the company. Learn More about insider trades at Zai Lab.
Information on this page was last updated on 8/16/2024.

Rafael Amado Insider Trading History at Zai Lab

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/15/2024	Sell	2,544	$18.86	$47,979.84	20,093
1/2/2024	Sell	19,363	$26.30	$509,246.90	22,637

Rafael Amado Buying and Selling Activity at Zai Lab

Zai Lab Company Overview

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Today's Range

Now: $30.43

$30.01

$30.79

50 Day Range

MA: $23.52

$17.55

$33.18

2 Week Range

Now: $30.43

$13.48

$36.60

Volume

335,994 shs

Average Volume

659,114 shs

Market Capitalization

$3.03 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

War on Elon Escalates…

From Porter & Company | Ad

One company holds a near-total monopoly on it.

Rafael Amado Biography and Net Worth

What is Rafael Amado's net worth?

How old is Rafael Amado?

What is Rafael Amado's salary?

How do I contact Rafael Amado?

Has Rafael Amado been buying or selling shares of Zai Lab?

Who are Zai Lab's active insiders?

Are insiders buying or selling shares of Zai Lab?